For intake "Utrozhestan" prescribed for premenstrual tension syndrome, dysmenorrhea, endocrine infertility, fibrocystic breast, hormone replacement therapy menopause (along with estrogen drugs), with a lack of progesterone inperimenopausal and premenopausal.
capsules for intravaginal application is used to maintain the luteal phase in preparation for IVF, in spontaneous or induced menstruation cycle.They are used as part of hormone replacement therapy with the missing (non-functioning) by the ovaries in the absence of progesterone to prevent a miscarriage, induced progestin insufficiency, with the threat of miscarriage.
other indications for "utrozhestan" are: premature menopause, endocrine infertility, endometriosis, menopause and postmenopause in combination with estrogen
When menopausal hormone replacement estrogens take "Utrozhestan" on 2 tab.per day for 10-12 days.During menopause drink on 1 tab.per day for 25 days.In case of insufficiency of the luteal phase (premenopausal, fibrocystic breast disease, dysmenorrhea, premenstrual tension syndrome) take medication during the second phase of the cycle periods for 10 days (from the 16th to the 25th day of the cycle).The daily amount is 200-300 mg (2-3 tablets), it must be divided into 2 doses (morning and evening).
In the case of complete absence of the body's progesterone enter the capsule of the drug into the vagina to 1 units per day on the 13th and 14th days of the cycle, and then from the 15th to 25th day of the cycle -on 1 piece 2 times per day.On the 26th day of pregnancy, and in determining the increase in the dose of 1 capsule per day each week, reaching a maximum number (6 caps. / Day), divided into 3 administration.Use the tool at this dose for 60 days.
In order to prevent a miscarriage, which may appear with a deficit of progesterone administered daily into the vagina 2-4 capsules 2-3 times a day up to 20 weeks of pregnancy.In order to maintain the luteal phase during the cycle of IVF intravaginal insert 4-6 caps.per day from the day of the injection of human chorionic gonadotropin to 20 weeks of pregnancy.